E

    enGene Holdings Inc. Common Stock (ENGN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.84
    +0.01 (+0.82%)

    Market Cap: $122.26M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    50%(5/10)
    Avg Surprise
    -6.44%
    Streak
    2 Q

    Upcoming Estimates

    Jul 31, 2026
    EPS Consensus$-0.43
    Range$-0.51 - $-0.35
    8 analysts
    EPS Revisions
    8
    0
    7d
    8
    0
    30d
    EPS Estimate Drift
    90d ago$-0.51-18.3%
    60d ago$-0.50-17.0%
    30d ago$-0.43+0.0%
    7d ago$-0.43+0.0%
    Current$-0.43
    Revenue Consensus
    $0
    Range$0 - $0
    8 analysts
    Oct 31, 2026
    EPS Consensus$-0.26
    Range$-0.48 - $-0.09
    9 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    8 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Oct 26EST
    		-$-0.26---
    Jul 26EST
    		-$-0.43---
    Apr 26
    		$-0.43$-0.48+10.42%Beat+15.7%
    Jan 26
    		$-0.44$-0.57+23.32%Beat+8.3%
    Oct 25
    		$-0.73$-0.58-25.86%Miss-114.7%
    Jul 25
    		$-0.57$-0.51-11.76%Miss-78.1%
    Apr 25
    		$-0.51$-0.48-6.25%Miss-34.2%
    Jan 25
    		$-0.48$-0.37-29.73%Miss-4.3%
    Oct 24
    		$-0.34$-0.36+5.56%Beat+92.5%
    Jul 24
    		$-0.32$-0.35+8.57%Beat-10222.6%
    Apr 24
    		$-0.38$-0.27-40.74%Miss-121.8%
    Jan 24
    		$-0.46$-0.47+2.13%Beat-1250.0%
    Oct 23
    		$-4.51N/AN/ABeat-11609.9%
    Jul 23
    		$-0.00N/AN/ABeat+84.5%
    Apr 23
    		$-0.17N/AN/ABeat-471.0%
    Jan 23
    		$0.04N/AN/ABeat+500.0%
    Oct 22
    		$0.04N/AN/ABeat-
    Jul 22
    		$-0.02N/AN/ABeat-
    Apr 22
    		$-0.03N/AN/ABeat-
    Jan 22
    		$-0.01N/AN/ABeat-
    Oct 21
    		$0.00$0.00N/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-0.85EV/EBITDA-6.01x
    Price/FCF-1.15xFCF Yield-86.82%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-52.60%ROIC-45.85%
    Financial Health
    Debt/Equity0.10xInterest Coverage-37.08x
    Current Ratio12.57xQuick Ratio12.57x
    Trading Statistics
    Beta-0.28Avg Volume695.58K
    52-Week High$12.2552-Week Low$1.40

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.83
    SMA 20$1.79
    SMA 50$1.81
    SMA 200$5.77
    EMA 10$1.83
    EMA 20$1.82
    EMA 50$2.04
    EMA 200$4.34

    MACD

    Line: 0.01Signal: -0.01Hist: 0.02

    ADX

    ADX: 18.1+DI: 25.5-DI: 17.9

    Aroon & PSAR

    Aroon Up88.0
    Aroon Down56.0
    PSAR$1.71

    Bollinger Bands

    Upper Band$1.94
    Lower Band$1.65
    %B Position1588%(Upper)
    Band Width0.66

    RSI (14-Day)

    Neutral
    51.2

    Momentum Oscillators

    Stoch %K68.4
    Stoch %D80.4
    Williams %R-37.9
    ROC (10d)8.2%
    Momentum0.14
    CCI (20d)59.0
    MFI (14d)57.5

    Volatility Measures

    ATR (14d)$0.08(4.4%)
    StdDev (20d)0.07
    Hist Vol51.8%(High)

    Volume Flow

    VWAP$1.83
    OBV14.2M
    AD Line-50.2M
    CMF (20d)0.114

    Volume Metrics

    Avg Vol (20d)704.1K
    Vol Ratio0.4x(Low)
    VWMA (20d)$1.80

    Pivot Points

    R3$1.99
    R2$1.95
    R1$1.89
    Pivot Point$1.85
    S1$1.79
    S2$1.75
    S3$1.69

    Advanced Oscillators

    TSI2.08
    Ultimate Osc52.2
    KST1.62

    Financial Data

    QuarterApr 2026Jan 2026Oct 2025Jul 2025Apr 2025Jan 2025Oct 2024Jul 2024Apr 2024Jan 2024Oct 2023Jul 2023
    Total Revenue$0$0$0$0$0$0$480,000$0$0$0$0$0
    Cost of Revenue$0$0$171,000$130,000$0$0N/A$0$0$0N/A$0
    Gross Profit$0$0$-171,000$-130,000$0$0$240,000$0$0$0N/A$0
    Operating Expenses$31.97M$31.18M$39.48M$29.95M$27.12M$26.61M$17.45M$16.76M$17.31M$10.77M$10.44M$6.25M
    R&D$22.20M$22.25M$31.72M$22.57M$20.21M$19.97M$11.27M$11.55M$9.86M$5.64M$5.67M$3.90M
    SG&A$9.77M$8.93M$10.02M$6.68M$6.92M$6.64M$6.18M$5.21M$7.46M$5.13M$4.77M$2.35M
    Operating Income$-31,968,000$-31,185,000$-39,481,000$-29,947,000$-27,124,000$-26,613,000$-17,455,000$-16,759,000$-17,310,000$-10,773,000$-10,442,000$-6,248,000
    Interest Income$2.66M$2.74M$1.98M$2.23M$2.49M$2.73M$3.02M$3.38M$2.98M$1.02M$407,000$394,000
    Interest Expense$745,000$1.22M$750,000$758,000$734,000$752,000$756,000$751,000$728,000$929,000$1.16M$1.44M
    Income Before Tax$-30,227,000$-29,752,000$-38,377,000$-28,752,000$-25,575,000$-24,598,000$-15,280,000$-14,177,000$-14,963,000$-10,741,000$-82,480,000$-4,720,000
    Income Tax Expense$0$0$-497,000$239,000$240,000$18,000$19,000$-29,000$21,000$-30,000$17,000$0
    Net Income$-30,227,000$-29,752,000$-37,880,000$-28,991,000$-25,815,000$-24,616,000$-15,299,000$-14,148,000$-14,984,000$-10,711,000$-82,497,000$-4,720,000
    EBITDA$-32,282,000$-31,587,000$-37,456,000$-27,864,000$-28,213,000$-27,293,000$-17,372,000$-16,724,000$-17,141,000$-10,757,000$-81,679,000$-3,629,000
    EBIT$-31,968,000$-31,185,000$-37,627,000$-27,994,000$-27,124,000$-26,613,000$-17,455,000$-16,806,000$-17,219,000$-10,837,000$-81,728,000$-3,672,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ENGN

    News

    Perceptive Advisors (NASDAQ: ENGN) discloses 9.99% beneficial stake with warrant cap

    Perceptive Advisors, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have reported a 9.99% beneficial ownership stake in enGene Holdings Inc. (NASDAQ: ENGN). This stake includes both common shares and pre-funded warrants, with the exercise of warrants capped at 9.99% ownership due to a beneficial ownership limitation. The filing details the breakdown of direct share holdings and exercisable warrants, emphasizing shared voting and dispositive power among the reporting persons.

    Stock Titan•8/14/26•
    Neutral

    enGene Holdings (ENGN): Venrock investor group reports 0.0% stake and no voting power

    An amended Schedule 13G/A filing for enGene Holdings Inc. (ENGN) indicates that a group of Venrock-affiliated investment entities and two individuals now report a 0.0% beneficial ownership of the company's Common Shares as of June 30, 2026. This means the group, previously significant holders, no longer maintains a reportable equity position of 5% or more in enGene. The filing confirms that each reporting person holds 0 Common Shares with no voting or dispositive power.

    Stock Titan•8/14/26•
    Neutral

    enGene Holdings Inc (ENGN) Earnings Forecast: Future EPS & Revenue Growth Estimates

    This article provides an earnings forecast for enGene Holdings Inc (ENGN), highlighting analyst ratings and future EPS and revenue growth estimates. Based on 12 analysts, the stock has a "Buy" rating with a target price indicating a 325.00% upside. The article also notes the company's recent EPS performance and future expectations.

    TradingKey•8/6/26•
    Bullish

    enGene Therapeutics Inc. (ENGN) Stock Price, News, Quote & History

    enGene Therapeutics Inc. (ENGN) is a clinical-stage biotechnology company focused on developing genetic medicines for bladder cancer, with its lead product candidate, detalimogene voraplasmid, in development for non-muscle invasive bladder cancer. The company's stock is currently trading at $1.8150, showing a +0.83% change today, and has experienced significant declines year-to-date and over the last year. Analysts have a target estimate of $3.29, with a recent downgrade to Underweight by Morgan Stanley.

    Yahoo! Finance Canada•8/5/26•
    Neutral

    Guggenheim downgrades Engene stock rating on weaker trial data

    Guggenheim downgraded Engene Holdings Inc. (NASDAQ:ENGN) to Neutral from Buy following disappointing interim Phase 2 trial data for its drug detalimogene in bladder cancer, causing a 76% stock plunge. The analyst cited a decline in efficacy compared to prior analyses, placing the drug below contemporary therapies, and removed the price target. Despite the setback, the company maintains a strong current ratio and cash position, and other analysts still see potential upside.

    Investing.com•8/4/26•
    Bearish

    Frequently Asked Questions About ENGN

    Does ENGN pay dividends?
    enGene Holdings Inc. Common Stock (ENGN) does not currently pay a regular dividend.
    What is ENGN's market cap?
    enGene Holdings Inc. Common Stock (ENGN) has a market capitalization of $122.26M with a current stock price of $1.84.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In